BioSpace News Archive

Athersys, Inc. and University Hospitals Cleveland Medical Center announced that UH Cleveland is now open as the first clinical site for the MACOVIA trial.

ImmunoGen today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2020.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates. A live webcast will be available under “News & Events” in the Investors & Media section of the company’s website at orchard-tx.com. The conference call can be accessed by

Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in Bullous Pemphigoid Disease Area Index (BPDAI) score Nomacopan has potential to replace long term steroid treatment (standard of care), which has multiple adverse effects in this elderly and frail population Nomacopan granted orphan drug designation by the U.S. Food and Drug Administration (

On May 15, the Tuberous Sclerosis Alliance (TS Alliance) will join tuberous sclerosis complex (TSC) organizations around the world to observe the eighth annual TSC Global Awareness Day. On this day, thousands of individuals and families affected by TSC will come together to increase public awareness of the rare disease and share the

Hillrom Supports Global COVID-19 Response With New Critical Care Products and Expanded Production Company Provides Financial Update on COVID-19

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, May 7, 2020 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase 3 ULTIMATE MS program Annualized Relapse Rate of 0.07 observed at week 48 NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the multicenter Phase 2 trial evaluating ublituximab, the Company’s investigational, glycoengineered, anti-CD20 monoclon

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Elaine V. Jones, Ph.D., as chair of the board of directors. “

- Reports First-Quarter Diluted EPS of $2.02 on a GAAP Basis; Adjusted Diluted EPS of $2.42 - First-Quarter Net Revenues Were $8.619 Billion, an Increase of 10.1 Percent on a GAAP Basis, or 10.7 Percent Operationally - First-Quarter U.S. HUMIRA Net Revenues Were $3.656 Billion, an Increase of 13.7 Percent; Internationally, HUMIRA Net Revenues Were $1.047 Billion, a Decrease of 14.9 Percent on a Reported Basis, or 12.8 Percent Operationally, Due to Biosimilar Competition